EULAR PsA Update Emphasizes Safety, Non-MSK Manifestations EULAR PsA Update Emphasizes Safety, Non-MSK Manifestations

The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across disease manifestations, and eliminates systemic steroids.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news